4,074 Shares in IQVIA Holdings Inc. (NYSE:IQV) Acquired by Dohj LLC

Dohj LLC acquired a new position in IQVIA Holdings Inc. (NYSE:IQV) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 4,074 shares of the medical research company’s stock, valued at approximately $943,000.

Several other hedge funds also recently added to or reduced their stakes in the business. AdvisorNet Financial Inc boosted its position in shares of IQVIA by 327.6% during the fourth quarter. AdvisorNet Financial Inc now owns 124 shares of the medical research company’s stock worth $29,000 after buying an additional 95 shares during the period. BKM Wealth Management LLC purchased a new position in shares of IQVIA during the fourth quarter worth $32,000. Activest Wealth Management purchased a new position in shares of IQVIA during the fourth quarter worth $35,000. CVA Family Office LLC purchased a new position in shares of IQVIA during the fourth quarter worth $43,000. Finally, CoreFirst Bank & Trust purchased a new position in IQVIA in the third quarter valued at $44,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Stock Performance

Shares of IQV traded up $0.90 during midday trading on Friday, reaching $234.88. 697,640 shares of the stock were exchanged, compared to its average volume of 761,918. The business’s 50-day moving average price is $245.28 and its 200 day moving average price is $223.17. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.86 and a quick ratio of 0.86. IQVIA Holdings Inc. has a twelve month low of $167.42 and a twelve month high of $261.73. The company has a market capitalization of $42.63 billion, a price-to-earnings ratio of 32.22, a PEG ratio of 2.27 and a beta of 1.50.

IQVIA (NYSE:IQV) last posted its earnings results on Wednesday, February 14th. The medical research company reported $2.84 EPS for the quarter, topping analysts’ consensus estimates of $2.82 by $0.02. The business had revenue of $3.87 billion for the quarter, compared to analysts’ expectations of $3.80 billion. IQVIA had a return on equity of 29.32% and a net margin of 9.06%. The business’s revenue was up 3.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.54 earnings per share. On average, sell-side analysts expect that IQVIA Holdings Inc. will post 10.12 EPS for the current fiscal year.

Insider Activity at IQVIA

In related news, insider Eric Sherbet sold 1,000 shares of the business’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $241.50, for a total value of $241,500.00. Following the transaction, the insider now owns 20,836 shares in the company, valued at approximately $5,031,894. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, insider Eric Sherbet sold 1,000 shares of the business’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $241.50, for a total value of $241,500.00. Following the transaction, the insider now owns 20,836 shares in the company, valued at approximately $5,031,894. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Kevin C. Knightly sold 8,607 shares of IQVIA stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $250.17, for a total value of $2,153,213.19. Following the completion of the sale, the insider now directly owns 5,251 shares in the company, valued at approximately $1,313,642.67. The disclosure for this sale can be found here. Insiders have sold 41,285 shares of company stock worth $10,331,003 in the last quarter. Company insiders own 1.60% of the company’s stock.

Analyst Ratings Changes

IQV has been the subject of a number of recent research reports. BTIG Research initiated coverage on IQVIA in a report on Tuesday, February 13th. They issued a “buy” rating and a $285.00 target price for the company. Leerink Partnrs reiterated an “outperform” rating on shares of IQVIA in a report on Monday, February 26th. Robert W. Baird lifted their target price on IQVIA from $226.00 to $251.00 and gave the company a “neutral” rating in a report on Thursday, February 15th. Truist Financial raised their price target on IQVIA from $286.00 to $297.00 and gave the company a “buy” rating in a research note on Tuesday, February 27th. Finally, Barclays raised their price target on IQVIA from $260.00 to $265.00 and gave the company an “overweight” rating in a research note on Thursday, February 15th. Three analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and an average target price of $256.80.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.